by Clinical Neuropsychologist Online | Thursday, July 9, 2026 | Dementia
Abstract INTRODUCTION Lecanemab, the first disease-modifying therapy for Alzheimer’s disease (AD), mitigates pathology primarily by clearing amyloid plaques, but its impact on peripheral immunity remains unclear. METHODS To assess Lecanemab’s immunological...
by Clinical Neuropsychologist Online | Thursday, July 9, 2026 | Dementia
Abstract INTRODUCTION This study evaluated the diagnostic performance of the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio to detect amyloid positivity in patients with cognitive decline symptoms. METHODS The Lumipulse Plasma Ratio was evaluated using...
by Clinical Neuropsychologist Online | Thursday, July 9, 2026 | Dementia
Abstract INTRODUCTION The impact of different neuropathologies on deep brain structures remains to be understood. We examine subcortical and limbic volumetry in neurodegenerative diseases involving phosphorylated tau (p-tau), α-synuclein, and transactive response DNA...
by Clinical Neuropsychologist Online | Wednesday, July 8, 2026 | Dementia
Abstract INTRODUCTION The association of sleep duration with Alzheimer’s disease (AD) – related brain atrophy and cognition remains unclear. METHODS Among 38,816 participants in the UK Biobank, we examined the association between sleep duration and a...
by Clinical Neuropsychologist Online | Tuesday, July 7, 2026 | Dementia
Abstract INTRODUCTION In frontotemporal dementia (FTD), tau detaches from axonal microtubules and forms pathological aggregates. Rather than stabilizing microtubules, tau promotes labile microtubule domains, redefining its role in neurodegeneration and underscoring...
by Clinical Neuropsychologist Online | Tuesday, July 7, 2026 | Dementia
Dementia, Ahead of Print. Advance care planning is a crucial element of high-quality, person-centred end-of-life care for people with dementia; however, levels have remained persistently low. Recent debates have emphasised informal conversations within families....
